Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 111 publications
Intracellular Activation of Dual-Pharmacophore Artezomib Enhances Selective Cytotoxicity in Hematologic Malignancies.
Journal: Journal of medicinal chemistry
Published: May 02, 2026
CDK4/6 Inhibition Reverses MEIS2 Suppression of CRL4 CRBN to Enhance Immunomodulatory Drug Therapy in Multiple Myeloma.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025
Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.
Journal: Nature genetics
Published: June 09, 2025
Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis.
Journal: Leukemia & lymphoma
Published: January 05, 2025
Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide.
Journal: Blood cancer journal
Published: November 13, 2024
Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real-world data.
Journal: British journal of haematology
Published: October 08, 2024
Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study.
Journal: HemaSphere
Published: March 26, 2024
Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies.
Journal: JCO precision oncology
Published: January 18, 2024
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
Journal: Nature medicine
Published: June 18, 2023
Last Updated: 09/26/2026